L-PBF metal 3D printers installed at AmnovisAmnovis, a Belgian contract manufacturer known for its precision in 3-D printed medical devices and high-performance components, is celebrating five years in business. Since its founding in June 2020 by Peter Mercelis and Ruben Wauthle, the company has just shipped its 100,000th 3-D printed implant — which it says is “a testament to its rapid growth and unwavering commitment to quality”.
Ruben Wauthle, CEO and co-founder of Amnovis, said: “From day one, we wanted Amnovis to be more than just another supplier. We set out to build a company that consistently delivers high-quality parts, communicates transparently, and meets deadlines. Five years later, we are proud to say we are doing exactly that.”
With a customer acceptance rate exceeding 99.9% and an on-time delivery rate above 90% for three consecutive years, Amnovis has earned its reputation as a trusted partner in the medical device sector. The landmark 100,000th implant was
Promethean Restorative’s FDA-approved SI fixation device, manufactured and delivered by Amnovis to support the product’s launch.
Maintaining momentumThe company’s structured approach and regulatory expertise played a key role in the success of that launch, particularly through the use of Amnovis’s FDA Master File, which helped streamline the approval process. Glenn Bowman, Promethean Restorative’s president and CEO, said: “It accelerated our go-to-market timeline and reduced regulatory friction. Amnovis’s clarity in documentation and speed in execution helped us avoid delays and maintain momentum.”
Amnovis is scaling rapidly, with projections to ship more than 50,000 implants in 2025 alone—half of its five-year total in just one year. To meet this growing demand, the company is expanding its production capacity not only for medical devices but also for applications in aerospace, semiconductors, and advanced engineering.
Mr Wauthle added: “Innovation is in our DNA. We don’t just follow trends, we redefine the ‘state of the art’ in 3-D printing by bridging the gap between emerging technologies and scalable, real-world applications. That is what sets Amnovis apart.”
Over the past five years, Amnovis has developed and validated several breakthrough technologies. Among them is a heat-treatment–free titanium process, making it the only contract manufacturer to offer 3-D printed pure titanium that meets ASTM standards without post-processing. This material is now widely used in spine, CMF, and orthopaedic applications.
Patient-specific customisationAnother innovation is the concept of deformable implants, a patented approach that enables patient-specific customisation by deforming highly porous regions of standardised components. This method offers bespoke solutions at the cost of standard manufacturing and is being co-developed with customers for market entry.
Amnovis has also introduced CuperNova, a proprietary powder modification technique that enhances the laser absorptivity of copper alloys. This advancement improves shelf life and flowability, enabling 3-D printing with standard lasers. The company is now scaling both powder modification and pilot manufacturing lines for industrial use. Looking ahead, Amnovis is exploring multi-metal 3-D printing using L-PBF technology, which would allow components to be printed with two or more metals—a promising development for next-generation applications.
Mr Wauthle concluded: “As we look ahead, we are excited about the opportunities to scale our impact even further. We are building on a solid foundation of quality and reliability, and we are committed to turning cutting-edge ideas into real-world solutions for our customers.”